Clinical Trials Directory

Trials / Completed

CompletedNCT04918069

Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)

Single-blinded, Randomized Study of Capsaicin to Prevent Delayed Chemotherapy-induced Nausea and Vomiting

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
160 (actual)
Sponsor
Christian Medical College, Vellore, India · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Chemotherapy-induced nausea and vomiting (CINV) is one of the few most severe adverse effects of chemotherapy, which often panic patients undergoing cancer treatment. Though acute episodes of CINV are well controlled with pharmacologic agents, delayed CINV continues to present a treatment challenge. Significant progress has been made over the past many years in discovering the pathophysiology of CINV. Primarily, three areas in the brain including central pattern generator (CPG), nucleus tractus solitarius (NTS) and area postrema (AP) are implicated in generating emetic reflex in all types of CINV (anticipatory, acute and delayed). The latter two areas NTS and AP are located at the caudal end of the fourth ventricle of brain which lies outside of the blood brain barrier and hence are stimulated by agents present in either blood and/or cerebrospinal fluid (CSF). Furthermore, NTS and AP are rich in muscarinic, dopamine, serotonin, neurokinin (NK1) and histamine receptors which are particularly important in delayed CINV. Clinical trials of antimuscarinic, antidopaminergic, antihistaminic drugs to prevent CINV have yielded inconclusive results except for olanzapine which is known to act on multiple receptors in NTS/AP. Only NK1 antagonists (e.g. aprepitant) which prevent substance P (SP) from binding to NK1 receptors have shown promising results and are clinically used to prevent delayed CINV. SP is a tachykinin peptide encoded by TAC1 (tachykinin precursor 1) gene and is found abundant in both peripheral and CNS. NK1 receptors in NTS/AP upon binding with SP will generate emetic reflex which will trigger delayed CINV. Though the topical analgesic drug capsaicin is reported to interfere with endogenous SP, its antiemetic potential in CINV has not been studied. This study intend to explore the antiemetic potential of capsaicin which is known to interfere with SP release in the GIT and CNS.

Conditions

Interventions

TypeNameDescription
DRUGCapsaicinTopical capsaicin ointment
DRUGPlaceboTopical placebo ointment

Timeline

Start date
2019-10-18
Primary completion
2022-05-14
Completion
2022-05-14
First posted
2021-06-08
Last updated
2022-05-20

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT04918069. Inclusion in this directory is not an endorsement.